During the Semashko Russian Pharmaceutical Forum plenary session, Vikram Punia, President of the Pharmasyntez Group, emphasized the vital role of innovation and significant investment in determining the direction of Russia's pharmaceutical industry. Virkam pointed out that starting new production capacities requires a large investment and a long-term vision, the obstacles to the introduction of innovative developments.
Highlighting the company's latest achievements, Vikram Punia mentioned that three new medications, including Vamotinib, a third-generation tyrosine kinase inhibitor (TKI) with a high safety and efficacy profile for the treatment of oncological blood diseases, are scheduled to be commercialized soon. Medications to treat type 2 diabetes mellitus and prevent postoperative adhesions are also being developed.
The company's Head underlined that billions of rubles are invested annually in research and development of new medications. "This is the future of the pharmaceutical industry in Russia, so we bet on innovations," Punia said.
According to Vikram Punia, the Russian pharmaceutical market is stagnating after a period of rapid expansion fr om 2014 to 2020. He cited the need to strengthen scientific development capabilities and establish favorable conditions for the production of novel, domestic medications. He claims that experience from around the world demonstrates that big pharmaceutical companies introduce 30 to 35 new medications every year, generating billions of dollars in revenue and promoting the growth of the industry.
“Entrepreneurs, businesses lack ideas. Everyone produces the same products, generics, generic after generics, like a broken record. How can this situation be rectified? "To work and raise competencies in the direction of development and science", Vikram Punia clarified.
The President of Pharmasyntez also underlined the necessity of developing systems to encourage creative development and the significance of taking an individual approach to big domestic corporations. He provided an example of a successful biotechnology support model in China, wh ere the government actively funds the establishment of scientific labs and encourages the development of national champions.
Vikram Punia promised that the Pharmasyntez Group would keep investing heavily in the development and manufacturing of novel pharmaceuticals in Russia. Vikram affirmed his optimism for the domestic industry's future and underlined the significance of business and government collaboration in achieving successful outcomes